

## References

### Chapter 1: Tuberculosis in the United States

CDC. A strategic plan for the elimination of tuberculosis in the United States. *MMWR* 1989; 38 (Suppl No. S-3). [www.cdc.gov/mmwr/preview/mmwrhtml/00001375.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/00001375.htm)

CDC. *CDC's Response to Ending Neglect: The Elimination of Tuberculosis in the United States*. Atlanta, Ga: U.S. Department of Health and Human Services, CDC; 2002.

CDC. Controlling tuberculosis in the United States: Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. *MMWR* 2005; 54 (No. RR-12). [www.cdc.gov/mmwr/PDF/rr/rr5412.pdf](http://www.cdc.gov/mmwr/PDF/rr/rr5412.pdf)

CDC. Essential components of a tuberculosis prevention and control program: Recommendations of the Advisory Council for the Elimination of Tuberculosis. *MMWR* 1995; 44 (No. RR-11). [www.cdc.gov/mmwr/preview/mmwrhtml/00038823.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/00038823.htm)

CDC. Extensively drug-resistant tuberculosis—United States, 1993–2006. *MMWR* 2007; 56 (11): 250-3. [www.cdc.gov/mmwr/preview/mmwrhtml/mm5611a3.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5611a3.htm)

CDC. Guidelines for preventing opportunistic infections among HIV-infected persons—2002. *MMWR* 2002; 51 (No. RR-08). [www.cdc.gov/mmwr/preview/mmwrhtml/rr5108a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5108a1.htm)

CDC. Guidelines for preventing the transmission of *Mycobacterium tuberculosis* in health-care settings, 2005. *MMWR* 2005; 54 (No. RR-17). [www.cdc.gov/mmwr/preview/mmwrhtml/rr5417a1.htm?s\\_cid=rr5417a1\\_e](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5417a1.htm?s_cid=rr5417a1_e)

CDC. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. *MMWR* 2009; 58 (No. RR-4). [www.cdc.gov/mmwr/preview/mmwrhtml/rr58e324a1.htm?s\\_cid=rr58e324a1\\_e](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr58e324a1.htm?s_cid=rr58e324a1_e)

CDC. Guidelines for the investigation of contacts of persons with infectious tuberculosis. *MMWR* 2005; 54 (No. RR-15). [www.cdc.gov/mmwr/pdf/rr/rr5415.pdf](http://www.cdc.gov/mmwr/pdf/rr/rr5415.pdf)

CDC. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children. *MMWR* 2009; 58 (No. RR-11). [www.cdc.gov/mmwr/preview/mmwrhtml/rr58e0826a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr58e0826a1.htm)

CDC. Notice to Readers: Updated guidelines on managing drug interactions in the treatment of HIV-related tuberculosis. *MMWR* 2008; 57 (04): 98. [www.cdc.gov/mmwr/preview/mmwrhtml/mm5704a4.htm?s\\_cid=mm5704a4\\_e](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5704a4.htm?s_cid=mm5704a4_e)

CDC. Plan to combat extensively drug-resistant tuberculosis. *MMWR* 2009; 58 (RR-03).

[www.cdc.gov/mmwr/preview/mmwrhtml/rr5803a1.htm?s\\_cid=rr5803a1\\_e](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5803a1.htm?s_cid=rr5803a1_e)

CDC. Prevention and control of tuberculosis in correctional and detention facilities. *MMWR* 2006; 55 (No. RR-09). [www.cdc.gov/mmwr/PDF/rr/rr5509.pdf](http://www.cdc.gov/mmwr/PDF/rr/rr5509.pdf)

CDC. Reported HIV status of tuberculosis patients—United States, 1993–2005. *MMWR* 2007; 56 (42): 1103-6. [www.cdc.gov/mmwr/preview/mmwrhtml/mm5642a2.htm?s\\_cid=mm5642a2\\_e](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5642a2.htm?s_cid=mm5642a2_e)

CDC. Reported tuberculosis in the United States, 2012. Atlanta, Ga: U.S. Department of Health and Human Services, CDC; October 2012. [www.cdc.gov/tb/statistics/reports/2012/default.htm](http://www.cdc.gov/tb/statistics/reports/2012/default.htm)

CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. *MMWR* 2000; 49 (No. RR-6). [www.cdc.gov/mmwr/preview/mmwrhtml/rr4906a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4906a1.htm)

Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection — United States, 2004–2008. *MMWR* 2010; 59 (08):224–9.

[http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5908a3.htm?s\\_cid=mm5908a3\\_e](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5908a3.htm?s_cid=mm5908a3_e)

Adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection—United States, 2003. *MMWR* 2003; 52 (31):735-9. [www.cdc.gov/mmwr/preview/mmwrhtml/mm5231a4.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5231a4.htm)

Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations—United States, 2001. *MMWR* 2001; 50 (34):733-5. [www.cdc.gov/mmwr/preview/mmwrhtml/mm5034a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5034a1.htm)

Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection—New York and Georgia, 2000. *MMWR* 2001; 50 (15): 289-91. [www.cdc.gov/mmwr/preview/mmwrhtml/mm5015a3.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5015a3.htm)

CDC. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent *Mycobacterium tuberculosis* infection recommendations—United States, 2011. *MMWR* 2011; 60 (48): 1650–1653.

[http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6048a3.htm?s\\_cid=mm6048a3\\_w](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6048a3.htm?s_cid=mm6048a3_w)

Errata (February 3, 2012): <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6104a7.htm>

CDC. Treatment of tuberculosis. *MMWR* 2003; 52 (No. RR-11).

[www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm)

Errata (January 7, 2005): [www.cdc.gov/mmwr/preview/mmwrhtml/mm5351a5.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5351a5.htm)

CDC. Trends in tuberculosis morbidity—United States, 1992–2002. *MMWR* 2003; 52 (11): 217-22. [www.cdc.gov/mmwr/preview/mmwrhtml/mm5211a2.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5211a2.htm)

CDC. Trends in tuberculosis—United States, 2007. *MMWR* 2008; 57 (11): 281-285. [www.cdc.gov/mmwr/preview/mmwrhtml/mm5711a2.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5711a2.htm)

CDC. Tuberculosis elimination revisited: Obstacles, opportunities, and a renewed commitment. *MMWR* 1999; 48 (No. RR-9). [www.cdc.gov/mmwr/preview/mmwrhtml/rr4809a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4809a1.htm)

CDC. Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. *MMWR* 2009; 58 (01): 7-10. [www.cdc.gov/mmwr/preview/mmwrhtml/mm5801a3.htm?s\\_cid=mm5801a3\\_e](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5801a3.htm?s_cid=mm5801a3_e)

CDC. Updated guidelines for using interferon gamma release assays to detect *Mycobacterium tuberculosis* Infection — United States, 2010 *MMWR* 2010; 59 (RR-5); 1-25. [http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5905a1.htm?s\\_cid=rr5905a1\\_e](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5905a1.htm?s_cid=rr5905a1_e)

Institute of Medicine, Committee on Elimination of Tuberculosis in the United States. Geiter L J, editor. *Ending Neglect: The Elimination of Tuberculosis in the United States*. Washington, D.C., National Academy Press; 2000. [www.nap.edu/catalog/9837.html](http://www.nap.edu/catalog/9837.html)

World Health Organization. *A WHO/The Union Monograph on TB and Tobacco Control*. Geneva, Switzerland; 2007.

## Chapter 2: Transmission and Pathogenesis of Tuberculosis

American Thoracic Society and CDC. Diagnostic standards and classification of tuberculosis in adults and children. *Am J Respir Crit Care Med* 2000; 161 (4): 1376-1395. <http://ajrccm.atsjournals.org/cgi/reprint/161/4/1376>

American Thoracic Society and Infectious Diseases Society of America. Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *Am J Respir Crit Care Med* 2007; 175: 367-416. [www.thoracic.org/statements/resources/mtpi/nontuberculous-mycobacterial-diseases.pdf](http://www.thoracic.org/statements/resources/mtpi/nontuberculous-mycobacterial-diseases.pdf)

CDC. A strategic plan for the elimination of tuberculosis from the United States. *MMWR* 1989; 38 (Suppl No. S-3). [www.cdc.gov/mmwr/preview/mmwrhtml/00001375.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/00001375.htm)

CDC. Controlling tuberculosis in the United States: Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. *MMWR* 2005; 54 (No. RR-12).

[www.cdc.gov/mmwr/PDF/rr/rr5412.pdf](http://www.cdc.gov/mmwr/PDF/rr/rr5412.pdf)

CDC. Essential components of a tuberculosis prevention and control program: Recommendations of the Advisory Council for the Elimination of Tuberculosis. *MMWR* 1995; 44 (No. RR-11).

[www.cdc.gov/mmwr/preview/mmwrhtml/00038823.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/00038823.htm)

CDC. Extensively drug-resistant tuberculosis—United States, 1993–2006. *MMWR* 2007; 56 (11): 250-3.

[www.cdc.gov/mmwr/preview/mmwrhtml/mm5611a3.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5611a3.htm)

CDC. Guidelines for preventing the transmission of *Mycobacterium tuberculosis* in health-care settings, 2005. *MMWR* 2005; 54 (No. RR-17).

[www.cdc.gov/mmwr/preview/mmwrhtml/rr5417a1.htm?s\\_cid=rr5417a1\\_e](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5417a1.htm?s_cid=rr5417a1_e)

CDC. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. *MMWR* 2009; 58 (No. RR-4).

[www.cdc.gov/mmwr/preview/mmwrhtml/rr58e324a1.htm?s\\_cid=rr58e324a1\\_e](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr58e324a1.htm?s_cid=rr58e324a1_e)

CDC. Management of persons exposed to multidrug-resistant tuberculosis. *MMWR* 1992; 41 (No. RR-11): 59-71.

[www.cdc.gov/mmwr/preview/mmwrhtml/00031296.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/00031296.htm)

CDC. National action plan to combat multidrug-resistant tuberculosis. *MMWR* 1992; 41 (No. RR-11): 1-48.

[www.cdc.gov/mmwr/preview/mmwrhtml/00031159.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/00031159.htm)

CDC. Recommendations for prevention and control of tuberculosis among foreign-born persons: Report of the Working Group on Tuberculosis among Foreign-born Persons. *MMWR* 1998; 47 (No. RR-16).

[www.cdc.gov/mmwr/preview/mmwrhtml/00054855.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/00054855.htm)

CDC. *Reported Tuberculosis in the United States*, 2012. Atlanta, Ga: U.S. Department of Health and Human Services, CDC; 2013.

[www.cdc.gov/tb/statistics/reports/2012/default.htm](http://www.cdc.gov/tb/statistics/reports/2012/default.htm)

CDC. Screening for tuberculosis and tuberculosis infection in high-risk populations: Recommendations of the Advisory Council for the Elimination of Tuberculosis. *MMWR* 1995; 44 (No. RR-11): 18-34.

[www.cdc.gov/mmwr/preview/mmwrhtml/00038873.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/00038873.htm)

CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. *MMWR* 2000; 49 (No. RR-6).

[www.cdc.gov/mmwr/preview/mmwrhtml/rr4906a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4906a1.htm)

Adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection—United States, 2003. *MMWR* 2003; 52 (31):735-9.

[www.cdc.gov/mmwr/preview/mmwrhtml/mm5231a4.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5231a4.htm)

Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations—United States, 2001. *MMWR* 2001; 50 (34):733-5. [www.cdc.gov/mmwr/preview/mmwrhtml/mm5034a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5034a1.htm)

Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection—New York and Georgia, 2000. *MMWR* 2001; 50 (15): 289-91. [www.cdc.gov/mmwr/preview/mmwrhtml/mm5015a3.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5015a3.htm)

CDC. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent *Mycobacterium tuberculosis* infection recommendations—United States, 2011. *MMWR* 2011; 60 (48): 1650–1653. [http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6048a3.htm?s\\_cid=mm6048a3\\_w](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6048a3.htm?s_cid=mm6048a3_w)

Errata (February 3, 2012): <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6104a7.htm>

CDC. Treatment of tuberculosis. American Thoracic Society, CDC, and Infectious Diseases Society of America. *MMWR* 2003; 52 (No. RR-11). [www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm)

Errata (January 7, 2005): [www.cdc.gov/mmwr/preview/mmwrhtml/mm5351a5.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5351a5.htm)

CDC. Tuberculosis elimination revisited: Obstacles, opportunities, and a renewed commitment. *MMWR* 1999; 48 (No. RR-9). [www.cdc.gov/mmwr/preview/mmwrhtml/rr4809a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4809a1.htm)

CDC. Updated guidelines for using interferon gamma release assays to detect *Mycobacterium tuberculosis* infection—United States, 2010. *MMWR* 2010; 59 (No. RR-05). [www.cdc.gov/mmwr/preview/mmwrhtml/rr5905a1.htm?s\\_cid=rr5905a1\\_e](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5905a1.htm?s_cid=rr5905a1_e)

### Chapter 3: Testing for Tuberculosis Disease and Infection

American Thoracic Society and CDC. Diagnostic standards and classification of tuberculosis in adults and children. *Am J Respir Crit Care Med* 2000; 161(4): 1376-1395. <http://ajrccm.atsjournals.org/cgi/reprint/161/4/1376>

CDC. A strategic plan for the elimination of tuberculosis in the United States. *MMWR* 1989; 38 (Suppl No. S-3). [www.cdc.gov/mmwr/preview/mmwrhtml/00001375.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/00001375.htm)

CDC. Controlling tuberculosis in the United States: Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. *MMWR* 2005; 54 (No. RR-12). [www.cdc.gov/mmwr/PDF/rr/rr5412.pdf](http://www.cdc.gov/mmwr/PDF/rr/rr5412.pdf)

CDC. Essential components of a tuberculosis prevention and control program: Recommendations of the Advisory Council for the Elimination of Tuberculosis. *MMWR* 1995; 44 (No. RR-11).

[www.cdc.gov/mmwr/preview/mmwrhtml/00038823.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/00038823.htm)

CDC. Guidelines for preventing the transmission of *Mycobacterium tuberculosis* in health-care settings, 2005. *MMWR* 2005; 54 (No. RR-17).

[www.cdc.gov/mmwr/preview/mmwrhtml/rr5417a1.htm?s\\_cid=rr5417a1\\_e](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5417a1.htm?s_cid=rr5417a1_e)

CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. *MMWR* 2000; 49 (No. RR-6). [www.cdc.gov/mmwr/preview/mmwrhtml/rr4906a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4906a1.htm)

Adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection—United States, 2003. *MMWR* 2003; 52 (31):735-9. [www.cdc.gov/mmwr/preview/mmwrhtml/mm5231a4.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5231a4.htm)

Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations—United States, 2001. *MMWR* 2001; 50 (34):733-5. [www.cdc.gov/mmwr/preview/mmwrhtml/mm5034a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5034a1.htm)

Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection—New York and Georgia, 2000. *MMWR* 2001; 50 (15): 289-91.

[www.cdc.gov/mmwr/preview/mmwrhtml/mm5015a3.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5015a3.htm)

[CDC. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent \*Mycobacterium tuberculosis\* infection](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6048a3.htm?s_cid=mm6048a3_w) recommendations—United States, 2011. *MMWR* 2011; 60 (48): 1650–1653.

[http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6048a3.htm?s\\_cid=mm6048a3\\_w](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6048a3.htm?s_cid=mm6048a3_w)

Errata (February 3, 2012): <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6104a7.htm>

CDC. The role of BCG vaccine in the prevention and control of tuberculosis in the United States: A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. *MMWR* 1996; 45 (No. RR-4).

[www.cdc.gov/mmwr/preview/mmwrhtml/00041047.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/00041047.htm)

CDC. Tuberculosis elimination revisited: Obstacles, opportunities, and a renewed commitment. *MMWR* 1999; 48 (No. RR-9). [www.cdc.gov/mmwr/preview/mmwrhtml/rr4809a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4809a1.htm)

CDC. Updated guidelines for using interferon gamma release assays to detect *Mycobacterium tuberculosis* infection—United States, 2010. *MMWR* 2010; 59 (No. RR-5).

[www.cdc.gov/mmwr/preview/mmwrhtml/rr5905a1.htm?s\\_cid=rr5905a1\\_e](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5905a1.htm?s_cid=rr5905a1_e)

## Chapter 4: Diagnosis of Tuberculosis

American Thoracic Society and CDC. Diagnostic standards and classification of tuberculosis in adults and children. *Am J Respir Crit Care Med* 2000; 161(4): 1376-1395.

<http://ajrccm.atsjournals.org/cgi/reprint/161/4/1376>

CDC. Controlling tuberculosis in the United States: Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. *MMWR* 2005; 54 (No. RR-12).

[www.cdc.gov/mmwr/PDF/rr/rr5412.pdf](http://www.cdc.gov/mmwr/PDF/rr/rr5412.pdf)

CDC. Essential components of a tuberculosis prevention and control program: Recommendations of the Advisory Council for the Elimination of Tuberculosis. *MMWR* 1995; 44 (No. RR-11).

[www.cdc.gov/mmwr/preview/mmwrhtml/00038823.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/00038823.htm)

CDC. Guidelines for preventing the transmission of *Mycobacterium tuberculosis* in health-care settings, 2005. *MMWR* 2005; 54 (No. RR-17).

[www.cdc.gov/mmwr/preview/mmwrhtml/rr5417a1.htm?s\\_cid=rr5417a1\\_e](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5417a1.htm?s_cid=rr5417a1_e)

CDC. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: Principles of therapy and revised recommendations. *MMWR* 1998; 47 (No. RR-20).

[www.cdc.gov/mmwr/preview/mmwrhtml/00055357.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/00055357.htm)

CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. *MMWR* 2000; 49 (No. RR-06). [www.cdc.gov/mmwr/preview/mmwrhtml/rr4906a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4906a1.htm)

Adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection—United States, 2003. *MMWR* 2003; 52 (31):735-9. [www.cdc.gov/mmwr/preview/mmwrhtml/mm5231a4.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5231a4.htm)

Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations—United States, 2001. *MMWR* 2001; 50 (34):733-5. [www.cdc.gov/mmwr/preview/mmwrhtml/mm5034a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5034a1.htm)

Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection—New York and Georgia, 2000. *MMWR* 2001; 50 (15): 289-91.

[www.cdc.gov/mmwr/preview/mmwrhtml/mm5015a3.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5015a3.htm)

CDC. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent *Mycobacterium tuberculosis* infection recommendations—United States, 2011. *MMWR* 2011; 60 (48): 1650–1653.

[http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6048a3.htm?s\\_cid=mm6048a3\\_w](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6048a3.htm?s_cid=mm6048a3_w)

Errata (February 3, 2012): <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6104a7.htm>

CDC. The role of BCG vaccine in the prevention and control of tuberculosis in the United States: A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. *MMWR* 1996; 45 (No. RR-4).

[www.cdc.gov/mmwr/preview/mmwrhtml/00041047.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/00041047.htm)

CDC. Treatment of tuberculosis. American Thoracic Society, CDC, and Infectious Diseases Society of America. *MMWR* 2003; 52 (RR-11). [www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm)

Errata (January 7, 2005): [www.cdc.gov/mmwr/preview/mmwrhtml/mm5351a5.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5351a5.htm)

CDC. Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. *MMWR* 2009; 58 (01): 7-10.

[www.cdc.gov/mmwr/preview/mmwrhtml/mm5801a3.htm?s\\_cid=mm5801a3\\_e](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5801a3.htm?s_cid=mm5801a3_e)

CDC. Updated guidelines for using interferon gamma release assays to detect *Mycobacterium tuberculosis* infection—United States, 2010. *MMWR* 2010; 59 (RR-5).

[www.cdc.gov/mmwr/preview/mmwrhtml/rr5905a1.htm?s\\_cid=rr5905a1\\_e](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5905a1.htm?s_cid=rr5905a1_e)

## Chapter 5: Treatment of Latent Tuberculosis Infection

CDC. Controlling tuberculosis in the United States: Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. *MMWR* 2005; 54 (No. RR-12).

[www.cdc.gov/mmwr/preview/mmwrhtml/rr5412a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5412a1.htm)

CDC. Guidelines for preventing the transmission of *Mycobacterium tuberculosis* in health-care settings, 2005. *MMWR* 2005; 54 (No. RR-17).

[www.cdc.gov/mmwr/preview/mmwrhtml/rr5417a1.htm?s\\_cid=rr5417a1\\_e](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5417a1.htm?s_cid=rr5417a1_e)

CDC. Guidelines for the investigation of contacts of persons with infectious tuberculosis: Recommendations from the National Tuberculosis Controllers Association and CDC. *MMWR* 2005; 54 (No. RR-15).

[www.cdc.gov/mmwr/preview/mmwrhtml/rr5415a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5415a1.htm)

CDC. Management of persons exposed to multidrug-resistant tuberculosis. *MMWR* 1992; 41 (RR-11): 59-71.

[www.cdc.gov/mmwr/preview/mmwrhtml/00031296.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/00031296.htm)

CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. *MMWR* 2000; 49 (No. RR-06).

[www.cdc.gov/MMWR/preview/MMWRhtml/rr4906a1.htm](http://www.cdc.gov/MMWR/preview/MMWRhtml/rr4906a1.htm)



Adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection—United States, 2003. *MMWR* 2003; 52 (31):735-9. [www.cdc.gov/mmwr/preview/mmwrhtml/mm5231a4.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5231a4.htm)

Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations—United States, 2001. *MMWR* 2001; 50 (34):733-5. [www.cdc.gov/mmwr/preview/mmwrhtml/mm5034a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5034a1.htm)

Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection—New York and Georgia, 2000. *MMWR* 2001; 50 (15): 289-91. [www.cdc.gov/mmwr/preview/mmwrhtml/mm5015a3.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5015a3.htm)

CDC. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent *Mycobacterium tuberculosis* infection. *MMWR* 2011; 60 (48): 1650-1653. [http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6048a3.htm?s\\_cid=mm6048a3\\_w](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6048a3.htm?s_cid=mm6048a3_w)

Errata (February 3, 2012): <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6104a7.htm>

## Chapter 6: Treatment of Tuberculosis Disease

CDC. Controlling tuberculosis in the United States: Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. *MMWR* 2005; 54 (No. RR-12). [www.cdc.gov/mmwr/preview/mmwrhtml/rr5412a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5412a1.htm)

CDC. National action plan to combat multidrug-resistant tuberculosis. *MMWR* 1992; 41 (RR-11): 1-48. [www.cdc.gov/mmwr/preview/mmwrhtml/00031159.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/00031159.htm)

CDC. Notice to Readers: Updated guidelines on managing drug interactions in the treatment of HIV-related tuberculosis. *MMWR* 2008; 57 (04): 98. [www.cdc.gov/mmwr/preview/mmwrhtml/mm5704a4.htm?s\\_cid=mm5704a4\\_e](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5704a4.htm?s_cid=mm5704a4_e)

CDC. Treating opportunistic infections among HIV-exposed and infected children. *MMWR* 2004; 53 (No. RR-14). [www.cdc.gov/mmwr/preview/mmwrhtml/rr5314a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5314a1.htm)

CDC. Treating opportunistic infections among HIV-infected adults and adolescents. *MMWR* 2004; 53 (No. RR-15). [www.cdc.gov/mmwr/preview/mmwrhtml/rr5315a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5315a1.htm)

CDC. Treatment of tuberculosis. American Thoracic Society, CDC, and Infectious Diseases Society of America. *MMWR* 2003; 52 (No. RR-11). [www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm)

Errata (January 7, 2005): [www.cdc.gov/MMWR/preview/MMWRhtml/mm5351a5.htm](http://www.cdc.gov/MMWR/preview/MMWRhtml/mm5351a5.htm)

## Chapter7: Infection Control in Health Care Settings

CDC. Guidelines for preventing the transmission of *Mycobacterium tuberculosis* in health-care settings, 2005. *MMWR* 2005; 54 (No. RR-17).

[www.cdc.gov/mmwr/preview/mmwrhtml/rr5417a1.htm?s\\_cid=rr5417a1\\_e](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5417a1.htm?s_cid=rr5417a1_e)

CDC. Prevention and control of tuberculosis in correctional and detention facilities: Recommendations from CDC. *MMWR* 2006; 55 (No. RR-09): 1-44.

[www.cdc.gov/mmwr/preview/mmwrhtml/rr5509a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5509a1.htm)

Curry International Tuberculosis Center (US). *Tuberculosis Infection Control: A Practical Manual for Preventing TB*; 2007. [www.currytbcenter.ucsf.edu/products/a-z\\_list.cfm](http://www.currytbcenter.ucsf.edu/products/a-z_list.cfm)